^
    Back
    Association details:
    Biomarker:EGFR L861Q
    Cancer:Non Small Cell Lung Cancer
    Drug:Lazcluze (lazertinib) (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Lazertinib for Patients With NSCLC Harboring Uncommon EGFR Mutations

    Excerpt:
    ...G719X, S768I, L861Q, G719X + S768I, G719X + L861Q, L861Q + S768I, L747S, S720A, E709A, exon 18 deletion) without common EGFR mutations including exon 19 deletion, L858R, exon 20 insertion, or T790M....
    Trial ID:
    LU21-16
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    IASLC-WCLC 2023
    Title:

    Lazertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Single-Arm, Phase II Multi-Center Trial

    Published date:
    08/08/2023
    Excerpt:
    The overall response rate was 44.1%, and disease control rate was 85.3%. Progression-free survival was 7.69 months (95% CI 4.4 - NA). Based on the mutation subtype, the response rate was as follows: G719X (n=13, 53.8%), L861Q (n=11, 54.6%)...In this study, we observed the clinical benefit of 240mg Lazertinib in the treatment of naïve EGFR uncommon mutants. Among the mutations, G719X and L861Q showed promising outcomes, which are aligned with preclinical data.